Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ten-eleven translocation 3 small interfering RNA
- Development stage
- Preclinical
- Lead developer
- Capital Medical University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
ten-eleven translocation 3 small interfering RNA (siTET3) is a nanoparticle-coated or liposomal nanoparticle (LNP)-encapsulated small interfering RNA designed to target and silence ten-eleven translocation 3 (TET3), a DNA methylcytosine dioxygenase that acts as a DNA methylation eraser. In Group 3 medulloblastoma (G3-MB), TET3 is recruited by the transcription factor OTX2 to catalyze active DNA demethylation at the Otx2 super-enhancer, promoting chromatin opening, tumor cell proliferation, and stemness. By silencing TET3, the siRNA impairs this hypomethylation feedback loop, reducing OTX2 expression and suppressing tumor progression. Preclinical studies in patient-derived orthotopic xenograft models of G3-MB have demonstrated that LNP-delivered siTET3 effectively suppresses tumor growth.
- Other names
- LNP-siTET3LNP-siTET-3LNP-siTET 3TET3 siRNATET-3 siRNATET 3 siRNAsiTET3-1siTET-3-1siTET 3-1siTET3-2siTET-3-2siTET 3-2siTET3-3siTET-3-3siTET 3-3ten-eleven translocation 3 siRNA
02
Targets
TET3 (Tet methylcytosine dioxygenase 3)
Beyond the preview
Go deeper on ten-eleven translocation 3 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ten-eleven translocation 3 small interfering RNA.